Search
Guanfacina: tractament del trastorn per dèficit d'atenció amb hiperactivitat (TDAH) en nens i adolescents de 6 a 17 anys quan els estimulants no són adequats, no es toleren o han mostrat ser ineficaços
(2017-10)
Attention Deficit Hyperactivity Disorder (ADHD) is a disorder of neurobiological origin that starts at the age of children and affects between 3% and 7% of school-age children. Race with three types of nonspecific symptoms: ...
Venetoclax en monoteràpia per al tractament de la leucèmia limfocítica crònica
(2019-02-01)
Chronic lymphocytic leukemia (LLC) is the most frequent type of leukemia in adults in the western world, representing 25-50% of all leukemia. The median age at diagnosis is 72 years and only 10% of patients are <55 years. ...
Àcid obeticòlic en combinació amb àcid ursodesoxicòlic (AUDC) per al tractament de la colangitis biliar primària que no respon adequadament a l’AUDC o en monoteràpia en adults que no toleren l’AUDC: informe d’avaluació de resultats
(2020-12)
Primary biliary cholangitis (CBP) is a chronic liver disease of autoimmune pathogenesis with a progressive clinical course that evolves over decades. It is characterized by a destruction of the intrahepatic bile ducts with ...
Durvalumab per al tractament del càncer de pulmó no microcític estadi III irresecable
(2020-03-25)
Non-microcytic lung cancer (CPNM) in stage III consists of a heterogeneous population with two subsets: stage IIIA and IIIB. Most patients with stage IIIA / B have an inoperable (non-resectable) disease. Only a third of ...
Upadacitinib per al tractament de l’artritis reumatoide de moderada a greu
(2021-03-03)
Rheumatoid arthritis (RA) is an inflammatory disease of autoimmune etiology characterized by chronic inflammation of the synovial membrane, which leads to the progressive destruction of joint structures. Typical symptoms ...
Axicabtagen ciloleucel i tisagenlecleucel per al tractament del limfoma B de cèl·lules grans
(2019-03-21)
Axicabtagen ciloleucel and tisagenlecleucel are two gene therapies that contain
T-lymphocytes of the patient previously manipulated so they express themselves
membrane, chimeric antigenic receptor or CAR. This receiver ...